Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

NCT03989115 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

113

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: RMC-4630
DRUG: Cobimetinib
DRUG: Drug: Osimertinib

Sponsor

Revolution Medicines, Inc.

Collaborators

[object Object]